If you’ve been diagnosed with ductal carcinoma in situ (DCIS), you may be wondering: Will my DCIS become invasive breast cancer? It’s one of the most important questions in DCIS care, and right now no one can predict with certainty how an individual case will behave. A new study published October 20, 2026, in Cell Reports Medicine offers an intriguing clue.
We’re proud to share that DCIS Understood founder Julia Stalder had a letter to the editor published in The Washington Post on October 16. The letter responds to a national conversation about ductal carcinoma in situ (DCIS) that matters to every woman facing this diagnosis.
A DCIS diagnosis – short for ductal carcinoma in situ, sometimes called “Stage 0” breast cancer – can leave you with more questions than answers. In a new patient perspective published in the Journal of Patient Experience, DCIS Understood founder Julia Stalder shares her own diagnosis story and lays out a roadmap for more transparent, patient-centered DCIS care.
DCIS HomeSearchAppeal2026-11-17T21:14:55+00:00
- Ann H. Partridge, MD, MPH
"I want patients to understand their options and have choices."
- Lawrence J. Solin, MD
We need to tailor therapies better for individual patients….the problem is that we overtreat the many to benefit the few."
- Shelley Hwang, MD, MPH
"There is risk both with treatment and with treatment deescalation, and we need to be able to quantify that trade off in a much better way for an individual patient."
- Lars J. Grimm, MD, MHS
"The next few years will witness the publication of major trial results and potentially chart a new course of DCIS management."
Demystifying
Ductal Carcinoma in Situ


